Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
argenx SEFRA:1AE +0.28%78 Equity-to-Asset is 0.84 as of Jun. 2026, which is 6% below its 10-year median of 0.89. GuruFocus rates FRA:1AE with a GF Score™ of 78/100 and a GF Value™ of €1,342.94 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 1,410 Biotechnology companies, argenx SE ranks better than 71.63% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. argenx SE's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €7,362 Mil. argenx SE's Total Assets for the quarter that ended in Jun. 2026 was €8,775 Mil.
Therefore, argenx SE's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.84.
The historical rank and industry rank for argenx SE's Equity-to-Asset or its related term are showing as below:
FRA:1AE'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.6 Med: 0.89 Max: 0.93
Current: 0.84
During the past 13 years, the highest Equity to Asset Ratio of argenx SE was 0.93. The lowest was 0.60. And the median was 0.89.
FRA:1AE's Equity-to-Asset is ranked better than 71.63% of 1410
companies
in the Biotechnology industry
Industry Median: 0.69
vs FRA:1AE: 0.84
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
argenx SE Equity-to-Asset Related Terms
argenx SE Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for argenx SE's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1AE vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, argenx SE's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where argenx SE's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
argenx SE's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (FRA:1AE) has a Equity-to-Asset of 0.84 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on argenx SE and its competitors. This is near median its historical median of 0.89. Over the past decade, argenx SE's Equity-to-Asset has ranged from 0.60 to 0.93. According to the industry distribution chart, argenx SE ranks #400 out of 1410 companies in the Biotechnology industry, placing it in the top 28.4%.
Is argenx SE's Equity-to-Asset too high?
argenx SE's current Equity-to-Asset of 0.84 is near median its 10-year median of 0.89. Over the past 10 years, this metric has ranged from a low of 0.60 to a high of 0.93. The Biotechnology industry median Equity-to-Asset is 0.69. argenx SE's value of 0.84 is 21.7% above this industry median. Based on the distribution chart, argenx SE ranks #400 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #400 out of 1410 companies for Equity-to-Asset. This puts argenx SE in the upper half of its industry. The industry median Equity-to-Asset is 0.69. argenx SE's value of 0.84 is 21.7% above this benchmark. Historically, argenx SE's own Equity-to-Asset has ranged from 0.60 to 0.93 over the past decade. While the company's 10-year median is 0.89 vs. the industry median of 0.69, argenx SE has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. argenx SE's current Equity-to-Asset of 0.84 is 21.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on argenx SE and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. argenx SE's current Equity-to-Asset is 0.84, which is near median its own 10-year median of 0.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (FRA:1AE) is currently considered Significantly Undervalued. The stock's GF Value™ is €1,342.94, compared to a current price of €858.80 — trading 36.1% below its estimated fair value. The current Equity-to-Asset is 0.84, which is near median its 10-year median of 0.89 and 21.7% above the Biotechnology industry median of 0.69. argenx SE's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For argenx SE (FRA:1AE), the current Equity-to-Asset is 0.84 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (FRA:1AE) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of €858.80 is trading 36.1% below its estimated GF Value™ of €1,342.94.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for FRA:1AE:
Equity-to-Asset: 0.84 (near median its 10-year median of 0.89)
GF Value™: €1,342.94 vs. price of €858.80 (36.1% below fair value)
Industry Position: 21.7% above the Biotechnology median (#400 of 1410)
No single metric tells the full story. See the FRA:1AE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score
Get the complete analysis for FRA:1AE
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1AE has been successfully added to your 
